Branka Mitić

Branka Mitić

Auto-generated profile, based on publicly available information

Branka Mitić

Clinic of Nephrology, University Clinical Center Nis, Nis, Serbia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Kidney International
Verified
Journal Article
Closed access
BRBrad H. Rovin
Brad H. Rovin
NSNeil Solomons
Neil Solomons
MDMary Anne Dooley
Mary Anne Dooley
JTJames Tumlin
James Tumlin
LLLidia Lysenko
Lidia Lysenko
KNKajohnsak Noppakun
Kajohnsak Noppakun

5 October 2018 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
WLWeiwei Li
Weiwei Li
CCChi-Kong Chan
Chi-Kong Chan
YLYushuo Liu
Yushuo Liu
JYJing Yao
Jing Yao
BMBranka Mitić
Branka Mitić
WCWan Chan
Wan Chan

27 November 2017 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
VŽValentina Živković
Valentina Živković
TCTatjana Cvetković
Tatjana Cvetković
BMBranka Mitić
Branka Mitić
BSBojana Stamenković
Bojana Stamenković
SSSonja Stojanović
Sonja Stojanović
VJVladimir Jurisic
Vladimir Jurisic

1 January 2019 in The Tohoku Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ZDZorica Dimitrijevic
Zorica Dimitrijevic
SSSonja S Salinger
Sonja S Salinger
RJRadmilo J. Jankovic
Radmilo J. Jankovic
BMBranka P. Mitic
Branka P. Mitic
Oxidative stress (OS) frequently contributes to the development of acute kidney injury (AKI). Iron can promote oxidative stress and tissue injury by catalyzing free reactive oxygen species (ROS) generation and increasing the steady-state concentration of these potent oxidants. The anticipated role of ferritin is to protect from OS by sequestering iron and limiting its involvement in reactions that generate ROS. In this prospective study, we aimed to investigate the association between serum ferritin levels and kidney function recovery among patients with AKI. Renal recovery was determined as a return of serum creatinine to less than 1.25 times the baseline value after 90 days of follow-up. One hundred twelve patients (72 males and 40 females, 63.68 ± 10.6 years old) were included in the final analysis. They were divided into AKI recovery (n = 76) and non-recovery groups (n = 36). Ferritin levels on admission were higher in AKI recovery group [284 (IQR 153-525) ng/mL] compared with the non-recovery group [127.4 (IQR 30-243) ng/mL], p < 0.001. Serum ferritin levels and the renal recovery significantly positively correlated (r = 0.72, p < 0.001). In multiple linear regression analysis, higher serum ferritin was associated with renal function recovery (OR 3.68, CI 2.02-3.97, p < 0.001). The optimal cut-off point of 240.5 ng/mL was determined for serum ferritin, which showed a sensitivity of 75.8% and a positive predictive value of 90%. In conclusion, serum ferritin levels on admission may be used as a prognostic marker for predicting renal recovery in AKI patients.

1 January 2014 in Srpski arhiv za celokupno lekarstvo
Verified
Journal Article
Open access
PDF file
VZValentina Zivkovic
Valentina Zivkovic
ASAleksandra Stankovic
Aleksandra Stankovic
TCTatjana Cvetkovic
Tatjana Cvetkovic
BMBranka Mitic
Branka Mitic
SKSvetislav Kostic
Svetislav Kostic
BSBojana Stamenkovic
Bojana Stamenkovic
Introduction. In spite of the growing number of reports on the study of anti-nucleosome and anti-C1q antibodies, there are still controversies on their significance as disease activity markers in patients with systemic lupus erythematosus (SLE) and their use in everyday clinical practice. Objective. Our aim was to assess the presence of anti-dsDNA, anti-nucleosome and anti-C1q antibodies in SLE patients, as well as to establish their sensitivity, specificity, positive and negative predictive value, and their correlation with SLE and lupus nephritis clinical activity. Methods. The study enrolled 85 patients aged 45.3?9.7 years on the average, with SLE of average duration 10.37?7.99 years, hospitalized at the Institute ?Niska Banja? during 2011, and 30 healthy individuals as controls. Disease activity was assessed using Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). In all examinees the levels of anti-dsDNA, anti-nucleosome and anti-C1q antibodies were measured using the ELISA method with Alegria Test Strips Orgentec (Germany). Results. Patients with active lupus nephritis had a higher presence of anti-C1q antibodies and higher co-positivity of anti-dsDNA, anti-nucleosome, and anti-C1q antibodies compared to those with inactive lupus nephritis (77.77% vs. 21.74%; p<0.01). SLE patients with SLEDAI ?11 had a higher presence of antinucleosome (93.75% vs. 64.15%; p<0.01) and anti-C1q antibodies (46.87% vs. 22.64%; p<0.05), as well as a higher mean level of anti-nucleosome antibodies (107.79?83.46 U/ml vs. 57.81?63.15 U/ml; p<0.05), compared to those with SLEDAI of 0-10. There was a positive correlation between the SLEDAI and the level of anti-dsDNA (r=0.290; p<0.01), anti-nucleosome (r=0.443; p<0.001), and anti-C1q antibodies (r=0.382; p<0.001). Only anti-C1q antibodies demonstrated correlation with proteinuria (r=0.445; p<0.001). Conclusion. Anti-nucleosome and anti-C1q antibodies demonstrated association with SLE and lupus nephritis activity, suggesting their potential usefulness in making predictions about lupus nephritis and assessment of disease activity.

6 June 2014 in Medical Principles and Practice
Verified
Journal Article
Open access
PDF file
JLJelena Lalić
Jelena Lalić
RVRadmila Veličković-Radovanović
Radmila Veličković-Radovanović
BMBranka Mitić
Branka Mitić
GPGoran Paunović
Goran Paunović
TCTatjana Cvetković
Tatjana Cvetković
Objectives: To assess the degree of immunosuppressive medication adherence in kidney transplant patients (KTPs) and to determine if there is a difference in the rate of adherence to tacrolimus (Tac), cyclosporine (CsA) and sirolimus (Sir). Subjects and Methods: From a total of 63 KTPs treated at the Clinic of Nephrology, Clinical Centre Niš, Serbia, 60 participated in the study by responding to questionnaires. They were divided into the adherence group (n = 43) and the nonadherence group (n = 17) according to their degree of adherence which was measured using a validated survey form, the simplified medication adherence questionnaire. The KTP adherence to the different immunosuppressive regimens (Tac, CsA and Sir) was compared. Statistical analysis was performed using the Student t test. Results: Adherence was observed in 43 (71.7%) patients, and only 17 (28.3%) did not follow the prescribed therapy. The estimated glomerular filtration rate was significantly lower in the nonadherence group (38.52 ± 18.22 ml/min) than in the adherence group (52.43 ± 16.91 ml/min, p < 0.05). With regard to the Tac level, a significant difference was also found between the adherers and the nonadherers (6.30 ± 2.06 vs. 5.0 ± 1.52 ng/ml, p < 0.05). Conclusion: The KTPs in this study demonstrated a high level of adherence. Nonadherence was associated with worse graft function and a lower Tac level. Knowledge about the degree of adherence could help the early identification of nonadherent patients and the development of strategies to improve this.